Population pharmacokinetics and pharmacodynamics of the anti-cd11a antibody hu1124 in human subjects with psoriasis

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 27, Issue 4, 1999, Pages 397-420

  Bauer, Robert J ^a   Dedrick, Russell L ^a   White, Mark L ^a   Murray, Michael J ^a   Garovoy, Marvin R ^a  

^a XOMA Corporation   (United States)

Author keywords

CD11a; CD3 positive lymphocytes; Hu1124; Pharmacokinetics; Psoriasis

Indexed keywords

ANTIBODY; CD11A ANTIBODY; CD3 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CHIMPANZEE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; MALE; MICHAELIS MENTEN KINETICS; MODEL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS;

EID: 0033506984     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. C. Dubey and M. Croft. Accessory molecule recognition of naive CD4 T cell activation. Immunol. Res. 15:114-125 (1996).
2. J. E. K. Hildreth, F. M. Gotch, P. D. K. Hildreth, and A. J. McMichael. A human lymphocyte-associated antigen involved in cell-mediated lympholysis. Eur. J. Immunol. 13:202-208 (1983).
3. A. Fischer, A. Durandy, G. Sterkers, and C. Griscelli. Role of the LFA-1 molecule in cellular interactions required for antibody production in humans. J. Immunol. 136:3198-3203 (1986).
4. J. E. K. Hildreth and J. T. August. The human lymphocyte function-associated (HLFA) antigen and a related macrophage differentiation antigen (HMac-1): Functional effects of subunit-specific monoclonal antibodies. J. Immunol. 134:3272-3280 (1985).
5. M. L. Dustin and T. A. Springer. LFA-1 interaction with ICAM-1 is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J. Cell Biol. 107:321 (1988).
6. W. A. Werther, T. N. Gonzalez, S. J. O'Connor, S. McCabe, B. Chan, T. Hotaling, M. Champe, J. A. Fox, P. M. Jardieu, P. W. Berman, and L. G. Presta. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J. Immunol. 157:4986-4995 (1996).
7. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nature Med. 1:442-447 (1995).
8. W. Krzyzanski and W. J. Jusko. Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions. J. Pharmacokin. and Biopharm. 26:385-408 (1998).
9. D. Z. D'Argenio and A. Schumitzky. ADAPT II User's Guide, Release 4. Biomedical Resource, U. Southern California, Los Angeles, 1997.
10. A. J. Boeckmann, L. B. Sheiner, and S. L. Beal. NONMEM V User's Help Guide. NONMEM Project Group, U. California at San Francisco, 1998.
11. M. O. Karlsson, E. N. Jonsson, C. G. Wiltse, and J. R. Wade. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J. Pharmacokin. Biopharm. 26:207-246 (1998).
12. W. A. Colburn. Specific antibodies and Fab fragments to alter the pharmacokinetics and reverse the pharmacologie/toxicologie effects of drugs. Drug Metab. Rev. 11:223-262 (1980).
13. T. A. Waldmann and W. Strober. Metabolism of immunoglobulins. Prog. Allergy 13:1-110 (1969).
14. T. A. Waldmann, W. Strober, and R. M. Blaese. Variations in the metabolism of immunoglobulins measured by turnover rates. In E. Merler (ed.), Immunoglobulins-Biological Aspects and Uses, National Academy of Sciences, Washington, DC, 1970, pp. 33-51.
15. J. S. Sancho, E. Gonzalez, J. F. Escanero, and J. Egido. Binding kinetics of monomeric and aggregated IgG to Kupffer cells and hepatocytes of mice. Immunology 53:283-289 (1984).
16. N. R. Srinivas, R. S. Weiner, W. C. Shyu, J. D. Calore, D. Trischler, L. K. Tay, J. S. Lee, D. S. Greene, and R. H. Barbhaiya. A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice. J. Pharm. Sci. 85:296-298 (1996).
17. D. M. Sheeley, B. M. Merrill, and L. C. E. Taylor. Characterization of monoclonal antibody glycosylation: Comparison of expression systems and identification of terminal α-linked galactose. Anal. Biochem. 247:102-110 (1997).
18. F. H. Routier, M. J. Davies, K. Bergemann, and E. F. Hounsell. The glycosylation pattern of a humanized IgG1 antibody (D1.3) expressed in CHO cells. Glyconjugate J. 14:201-207 (1997).
19. P. S. Linsley, W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174:561-569 (1991).
20. P. S. Linsley, P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792-795 (1992).
21. N. R. Srinivas, R. S. Weiner, G. Warner, W. C. Shyu, T. Davidson, C. G. Fadrowski, L. K. Tay, J. S. Lee, D. S. Greene, and R. H. Barbhaiya. Pharmacokinetics and pharmacodynamics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses. J. P harm. Sci. 85:1-4 (1996).
22. P. K. T. Li, M. G. Nicholls, and K. N. Lai. The complications of newer transplant antirejection drugs: treatment with cyclosporin A, OKT3, and FK506. Adverse Drug React. Acute Poisoning Rev. 9:123-155 (1990).
23. G. Goldstein, J. N. Douglas, K. R. Henell, and I. L. Smith. Pharmacokinetic study of Orthoclone OKT3 serum levels during treatment of acute renal allograft rejection. Transplantation 46:587-589 (1988).